Finasterid (Indonesian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Finasterid" in Indonesian language version.
refsWebsite
Global rank
Indonesian rank
1st place
1st place
3rd place
6th place
low place
low place
5th place
7th place
low place
low place
books.google.com
- Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry (edisi ke-6th). Lippincott Williams & Wilkins. hlm. 1286–. ISBN 978-0-7817-6879-5. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Blume-Peytavi U, Whiting DA, Trüeb RM (2008-06-26). Hair Growth and Disorders. Springer Science & Business Media. hlm. 369. ISBN 978-3-540-46911-7. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Sataloff RT, Sclafani AP (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. hlm. 400–. ISBN 978-93-5152-459-5. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Habif TP (23 April 2015). Clinical Dermatology. Elsevier Health Sciences. hlm. 934–. ISBN 978-0-323-26607-9. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Wolverton SE (2007). Comprehensive Dermatologic Drug Therapy. Elsevier Health Sciences. ISBN 978-1-4377-2070-9.
doi.org
- Knezevich EL, Viereck LK, Drincic AT (2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828.
- Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.
- Varothai S, Bergfeld WF (2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508.
- Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS (2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU Int. 106 (10): 1444–51. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593.
- Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM (2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. 110 (11): 1208–1215. doi:10.1093/jnci/djy035. PMID 29534197.
- Kanti V., Messenger A., Dobos G., Reygagne P., Finner A., Blumeyer A., Trakatelli M., Tosti A., Del Marmol V., Piraccini B. M., Nast A., Blume-Peytavi U. (2018). "Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version". Eur Acad Dermatol Venereol. 32 (1): 11–22. doi:10.1111/jdv.14624.
- Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–56. doi:10.2147/IJWH.S49337. PMC 3769411
. PMID 24039457. - Trüeb, Ralph M. (2017). "Discriminating in favour of or against men with increased risk of finasteride-related side effects?". Experimental Dermatology. 26 (6): 527–528. doi:10.1111/exd.13155. ISSN 0906-6705. PMID 27489125.
[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]
- Traish AM (2012). "5α-reductases in human physiology: an unfolding story". Endocr Pract. 18 (6): 965–75. doi:10.4158/EP12108.RA. PMID 23246684.
- Walsh PC (2010). "Chemoprevention of prostate cancer". The New England Journal of Medicine. 362 (13): 1237–8. doi:10.1056/NEJMe1001045. PMID 20357287.
- Narula HS, Carlson HE (2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nat Rev Endocrinol. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235.
- Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307.
- Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF (April 2014). "Aldosterone antagonists for preventing the progression of chronic kidney disease". Cochrane Database of Systematic Reviews. 4 (4): CD007004. doi:10.1002/14651858.CD007004.pub3. PMID 24782282.
- Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–7. doi:10.4103/0253-7613.59929. PMC 2846505 . PMID 20407562.
- Trost L, Saitz TR, Hellstrom WJ (2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sex Med Rev. 1 (1): 24–41. doi:10.1002/smrj.3. PMID 27784557.
- Locci A, Pinna G (2017). "Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment". Br. J. Pharmacol. 174 (19): 3226–3241. doi:10.1111/bph.13843. PMC 5595768 . PMID 28456011.
- Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718.
drugs.com
- "Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Diarsipkan dari versi asli tanggal 2018-08-25. Diakses tanggal 2019-03-05.
fda.gov
accessdata.fda.gov
- "Proscar label" (PDF). Diarsipkan (PDF) dari versi asli tanggal 2016-03-03. Diakses tanggal 2019-07-04.
- "Propecia label" (PDF). Diarsipkan (PDF) dari versi asli tanggal 2017-02-10. Diakses tanggal 2019-07-04.
- FDA. "Summary of Key Safety Findings" (PDF). hlm. 98. Diarsipkan (PDF) dari versi asli tanggal 2020-01-12. Diakses tanggal 2019-07-04.
fda.gov
- Food and Drugs Administration (2011-06-09). "5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer". Diarsipkan dari versi asli tanggal 2015-01-09. Diakses tanggal 2019-07-04.
google.ca
books.google.ca
- Ferri, Fred F. (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1. Elsevier Health Sciences. hlm. 580. ISBN 9780323084307.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 483. ISBN 9783527607495.
google.fr
books.google.fr
- Burchum J, Rosenthal L (2014-12-02). Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. hlm. 802. ISBN 978-0-323-34026-7.
mhra.gov.uk
- Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer Diarsipkan 2014-10-25 di Wayback Machine.
nih.gov
ncbi.nlm.nih.gov
- Knezevich EL, Viereck LK, Drincic AT (2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828.
- Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.
- Varothai S, Bergfeld WF (2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508.
- Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS (2010). "5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review". BJU Int. 106 (10): 1444–51. doi:10.1111/j.1464-410X.2010.09714.x. PMID 20977593.
- Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM (2018). "Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial". Journal of the National Cancer Institute. 110 (11): 1208–1215. doi:10.1093/jnci/djy035. PMID 29534197.
- Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS (2016). "Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review". J Clin Aesthet Dermatol. 9 (7): 56–62. PMC 5023004 . PMID 27672412.
- Levy LL, Emer JJ (August 2013). "Female pattern alopecia: current perspectives". International Journal of Women's Health. 5: 541–56. doi:10.2147/IJWH.S49337. PMC 3769411 . PMID 24039457.
- Trüeb, Ralph M. (2017). "Discriminating in favour of or against men with increased risk of finasteride-related side effects?". Experimental Dermatology. 26 (6): 527–528. doi:10.1111/exd.13155. ISSN 0906-6705. PMID 27489125.
[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]
- Traish AM (2012). "5α-reductases in human physiology: an unfolding story". Endocr Pract. 18 (6): 965–75. doi:10.4158/EP12108.RA. PMID 23246684.
- Walsh PC (2010). "Chemoprevention of prostate cancer". The New England Journal of Medicine. 362 (13): 1237–8. doi:10.1056/NEJMe1001045. PMID 20357287.
- Narula HS, Carlson HE (2014). "Gynaecomastia-pathophysiology, diagnosis and treatment". Nat Rev Endocrinol. 10 (11): 684–698. doi:10.1038/nrendo.2014.139. PMID 25112235.
- Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–795. doi:10.1517/14740338.2012.712109. PMID 22862307.
- Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF (April 2014). "Aldosterone antagonists for preventing the progression of chronic kidney disease". Cochrane Database of Systematic Reviews. 4 (4): CD007004. doi:10.1002/14651858.CD007004.pub3. PMID 24782282.
- Aiman U, Haseeen MA, Rahman SZ (December 2009). "Gynecomastia: An ADR due to drug interaction". Indian Journal of Pharmacology. 41 (6): 286–7. doi:10.4103/0253-7613.59929. PMC 2846505 . PMID 20407562.
- Trost L, Saitz TR, Hellstrom WJ (2013). "Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review". Sex Med Rev. 1 (1): 24–41. doi:10.1002/smrj.3. PMID 27784557.
- Locci A, Pinna G (2017). "Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment". Br. J. Pharmacol. 174 (19): 3226–3241. doi:10.1111/bph.13843. PMC 5595768 . PMID 28456011.
- Gur S, Kadowitz PJ, Hellstrom WJ (January 2013). "Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation". Expert Opinion on Drug Safety. 12 (1): 81–90. doi:10.1517/14740338.2013.742885. PMID 23173718.
pom.go.id
pionas.pom.go.id
- Badan Pengawas Obat dan Makanan. "Finasterid". Pusat Informasi Obat Nasional. Diarsipkan dari versi asli tanggal 2018-07-11. Diakses tanggal 2019-07-04.
uroweb.org
- "Treatment of Non-neurogenic Male LUTS | Uroweb". Diarsipkan dari versi asli tanggal 2019-04-06.
web.archive.org
- Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry (edisi ke-6th). Lippincott Williams & Wilkins. hlm. 1286–. ISBN 978-0-7817-6879-5. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Badan Pengawas Obat dan Makanan. "Finasterid". Pusat Informasi Obat Nasional. Diarsipkan dari versi asli tanggal 2018-07-11. Diakses tanggal 2019-07-04.
- "Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Diarsipkan dari versi asli tanggal 2018-08-25. Diakses tanggal 2019-03-05.
- Blume-Peytavi U, Whiting DA, Trüeb RM (2008-06-26). Hair Growth and Disorders. Springer Science & Business Media. hlm. 369. ISBN 978-3-540-46911-7. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- Sataloff RT, Sclafani AP (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. hlm. 400–. ISBN 978-93-5152-459-5. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- "Proscar label" (PDF). Diarsipkan (PDF) dari versi asli tanggal 2016-03-03. Diakses tanggal 2019-07-04.
- "Treatment of Non-neurogenic Male LUTS | Uroweb". Diarsipkan dari versi asli tanggal 2019-04-06.
- "Propecia label" (PDF). Diarsipkan (PDF) dari versi asli tanggal 2017-02-10. Diakses tanggal 2019-07-04.
- Habif TP (23 April 2015). Clinical Dermatology. Elsevier Health Sciences. hlm. 934–. ISBN 978-0-323-26607-9. Diarsipkan dari versi asli tanggal 2023-01-10. Diakses tanggal 2019-07-04.
- FDA. "Summary of Key Safety Findings" (PDF). hlm. 98. Diarsipkan (PDF) dari versi asli tanggal 2020-01-12. Diakses tanggal 2019-07-04.
- Food and Drugs Administration (2011-06-09). "5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer". Diarsipkan dari versi asli tanggal 2015-01-09. Diakses tanggal 2019-07-04.
- Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer Diarsipkan 2014-10-25 di Wayback Machine.
worldcat.org
- Trüeb, Ralph M. (2017). "Discriminating in favour of or against men with increased risk of finasteride-related side effects?". Experimental Dermatology. 26 (6): 527–528. doi:10.1111/exd.13155. ISSN 0906-6705. PMID 27489125.
[...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]